Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Peking University: Clinical Trials & FDA Approval Profile

Peking University (Global / Institutional) sponsors 56 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (9 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.1%
Median Closed Enrollment vs National (145 pts)33 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Peking University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)56
Active Pipeline (Recruiting Now)16 (9)
Completed vs Stopped Early5 / 4 (7.1%)
Median Closed Actual Enrollment33 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Peking University
Hospital Research SiteLocationShared Protocols
Beijing Cancer HospitalBeijing, Beijing Municipality17
Peking University Cancer HospitalBeijing5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Peking University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07127822Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Peking University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI